SKLZ Surges 74.8% After Analyst Upgrade; 5 Stocks With Major EPS Revisions
Skillz Inc led today's movers with a 74.8% rally after its forward EPS growth estimate was raised from 34.9% to 35.8%, while Bloom Energy climbed 33.5% on a 1.5 percentage point revision to 108.4% growth. Travere Therapeutics posted a 29.3% gain following a massive 29.1 percentage point upward revision to its EPS growth forecast.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SKLZ | Communication Services | 2026-04-12 | +1.0pp | +74.8% |
| XELB | Consumer Cyclical | 2026-04-10 | N/A | +48.1% |
| BE | Industrials | 2026-04-09 | +1.5pp | +33.5% |
| COSM | Healthcare | 2026-04-12 | N/A | +30.0% |
| TVTX | Healthcare | 2026-04-08 | +29.1pp | +29.3% |
Why did SKLZ stock jump in April 2026?
SKLZ jumped 74.8% (from $2.46 to $4.30) after analysts raised its forward EPS growth estimate from 34.9% to 35.8% on April 12.
The mobile gaming platform attracted aggressive buying as the screener flagged the upward revision ahead of the price surge. Communication Services sector momentum amplified gains as growth-oriented stocks rebounded. Institutional interest appeared to increase following the estimate change, confirming the revision signal.
View screener snapshot from 2026-04-12 →
FAQ: SKLZ
Why did SKLZ stock jump 74.8% on April 15, 2026?
SKLZ surged 74.8% after its forward EPS growth estimate was raised from 34.9% to 35.8%, with the stock moving from $2.46 to $4.30 between April 12 and April 15.
Is SKLZ a buy after the 74% rally?
The EPS revision to 35.8% growth suggests analyst confidence in Skillz's earnings trajectory is strengthening, though the 74.8% jump may have priced in near-term gains.
What caused SKLZ stock to surge?
SKLZ's surge followed a 1.0 percentage point upward revision to its forward EPS growth estimate, from 34.9% to 35.8%, which the screener detected on April 12 ahead of the price move.
Why did XELB stock jump in April 2026?
XELB climbed 48.1% (from $1.33 to $1.97) as the screener detected a 64.2% forward EPS growth estimate for the omnichannel lifestyle brand.
Small-cap consumer stocks rallied broadly during the detection window, with Xcel Brands outperforming on the earnings revision signal. No recent news was available, suggesting the move was driven by quantitative screens catching the estimate data. The Consumer Cyclical sector saw moderate strength during this period.
View screener snapshot from 2026-04-10 →
FAQ: XELB
Why did XELB stock jump 48% in April 2026?
XELB surged 48.1% after a 64.2% forward EPS growth estimate was detected, with shares rising from $1.33 to $1.97 between April 10 and April 15.
Is XELB a buy after the 48% rally?
The 64.2% EPS growth estimate indicates analyst optimism for Xcel Brands, but the 48.1% price jump may have limited immediate upside for new buyers.
What is XELB's EPS growth estimate?
Analysts project XELB will achieve 64.2% EPS growth next year, a strong figure that attracted buying during the April detection window.
Why did BE stock jump in April 2026?
BE gained 33.5% (from $160.13 to $213.84) after its forward EPS growth estimate was raised from 106.9% to 108.4% on April 9.
Bloom Energy, a clean energy fuel cell company, benefited from sector rotation into industrials with strong growth profiles. The 1.5 percentage point revision signaled accelerating profitability as management executes on hydrogen and data center power contracts. The Industrials sector showed particular strength during this rally window.
View screener snapshot from 2026-04-09 →
FAQ: BE
Why did BE stock climb 33.5% this week?
BE shares rallied 33.5% after its forward EPS growth estimate was increased from 106.9% to 108.4%, with the stock moving from $160.13 to $213.84 over six days.
What caused Bloom Energy's surge?
Bloom Energy's surge followed a 1.5 percentage point upward revision to its forward EPS growth estimate, from 106.9% to 108.4%, as investors rotated into industrial growth stocks.
Is BE stock a buy after the 33% gain?
With EPS growth now estimated at 108.4%, BE remains attractive for growth-focused portfolios, though investors should monitor whether the valuation has become stretched after the 33.5% rally.
Why did COSM stock jump in April 2026?
COSM surged 30.0% (from $0.30 to $0.39) as the screener flagged a 163.6% forward EPS growth estimate for the pharmaceutical distribution company on April 12.
Healthcare small-caps saw renewed interest, with Cosmos Health benefiting from its high-growth earnings profile. Penny stocks with aggressive EPS projections attracted speculative buying despite the elevated risk. The company operates in a sector where earnings momentum can quickly shift market sentiment.
View screener snapshot from 2026-04-12 →
FAQ: COSM
Why did COSM stock jump 30% in April 2026?
COSM climbed 30.0% after a 163.6% forward EPS growth estimate was detected, with shares rising from $0.30 to $0.39 between April 12 and April 15.
What caused Cosmos Health stock to surge?
Cosmos Health's surge was driven by a 163.6% forward EPS growth estimate that attracted speculative buying into the penny-stock healthcare name.
Is COSM a buy after the 30% rally?
The 163.6% EPS growth estimate is exceptional, but COSM's sub-dollar price and speculative nature warrant caution for risk-averse investors.
Why did TVTX stock jump in April 2026?
TVTX gained 29.3% (from $31.68 to $40.95) after analysts sharply raised its forward EPS growth estimate from 519.7% to 548.8% on April 8.
The rare disease biotech saw massive estimate revision momentum as investors anticipated regulatory catalysts for its kidney disease franchise. Healthcare growth stocks attracted capital rotation, with Travere's exceptional profitability trajectory standing out among peers. The 29.1 percentage point upward revision represented the most significant change among today's movers.
View screener snapshot from 2026-04-08 →
FAQ: TVTX
Why did TVTX stock jump 29.3% on April 15, 2026?
TVTX surged 29.3% after its forward EPS growth estimate was raised from 519.7% to 548.8%, with shares climbing from $31.68 to $40.95 between April 8 and April 15.
What caused Travere Therapeutics stock to rally?
Travere Therapeutics rallied following a massive 29.1 percentage point upward revision to its forward EPS growth estimate, from 519.7% to 548.8%, signaling expected profitability acceleration.
Is TVTX a buy after the 29% gain?
With EPS growth projected at 548.8%, TVTX shows exceptional profitability momentum, though investors should evaluate whether regulatory catalysts support the earnings trajectory.
Today's movers demonstrate that EPS estimate revisions continue to drive significant price action, with growth stocks across Healthcare and Industrials leading gains. The 74.8% surge in SKLZ and the aggressive 29.1 percentage point revision for TVTX highlight how even modest estimate changes can trigger substantial market responses when sentiment aligns with sector trends.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →